St Louis, Missouri
Cancer biologic therapy trials in St Louis, MO
67 cancer biologic therapy studies are recruiting participants at sites in St Louis as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
St Louis at a glance
- 67 studies are recruiting at a site in St Louis.
- By phase: Phase 1 (13), Phase 1/2 (4), Phase 2 (24), Phase 2/3 (1), Phase 3 (25).
- By sponsor: industry (24), university, hospital or other (22), government (21).
- By research area: Lymphoma (24), Lung Cancer (20), Breast Cancer (13), Melanoma (4), Prostate Cancer (4), Pancreatic Cancer (2).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in St Louis
Basic details from each study's public record (the 30 most recently updated of 67). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County · Washington University School of Medicine
- Registry record
- NCT03606967 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT05564377 · updated
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Siteman Cancer Center ( Site 0099)
- Registry record
- NCT06393374 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Washington University Siteman Cancer Center ( Site 0031)
- Registry record
- NCT06966700 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT06058377 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in St Louis, MO on ClinicalTrials.gov.
Lung cancer studies recruiting in St Louis
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South
- Registry record
- NCT06498635 · updated
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Registry record
- NCT06767514 · updated
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Washington University School of Medicine ( Site 3279)
- Registry record
- NCT07513376 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South
- Registry record
- NCT06096844 · updated
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Washington University School of Medicine ( Site 0024)
- Registry record
- NCT07221474 · updated
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Mercy Research - David C. Pratt Cancer Center ( Site 0006) · Mercy South - David M Sindelar Cancer Center ( Site 0098)
- Registry record
- NCT06312137 · updated
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT04181060 · updated
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Study site
- Washington University in St Louis
- Registry record
- NCT06667908 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in St Louis, MO on ClinicalTrials.gov.
Prostate cancer studies recruiting in St Louis
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT03866382 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in St Louis, MO on ClinicalTrials.gov.
Melanoma studies recruiting in St Louis
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital South · Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County
- Registry record
- NCT05136196 · updated
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Washington University School of Medicine
- Study site
- Washington University School of Medicine
- Registry record
- NCT05629546 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in St Louis, MO on ClinicalTrials.gov.
Lymphoma studies recruiting in St Louis
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Siteman Cancer Center at Christian Hospital
- Registry record
- NCT03739814 · updated
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Washington University School of Medicine
- Registry record
- NCT06317662 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Missouri Baptist Medical Center · Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County
- Registry record
- NCT06337318 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Missouri Baptist Medical Center
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cardinal Glennon Children's Medical Center · Mercy Hospital Saint Louis · Washington University School of Medicine
- Registry record
- NCT04546399 · updated
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mercy Hospital South
- Registry record
- NCT04840602 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cardinal Glennon Children's Medical Center · Mercy Hospital Saint Louis · Siteman Cancer Center at Christian Hospital
- Registry record
- NCT05675410 · updated
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County · Washington University School of Medicine
- Registry record
- NCT06649812 · updated
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Study site
- Washington University School of Medicine in St. Louis
- Registry record
- NCT07015242 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Mercy Hospital Saint Louis · Mercy Hospital South · Siteman Cancer Center-South County
- Registry record
- NCT03150693 · updated
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Phase 3
- Ages 60 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Mercy Hospital South · Siteman Cancer Center at Christian Hospital · Siteman Cancer Center-South County
- Registry record
- NCT05976763 · updated
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Allogene Therapeutics
- Study site
- Washington University School of Medicine - Siteman Cancer Center
- Registry record
- NCT06500273 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in St Louis, MO on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in St Louis
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Washington University School of Medicine
- Registry record
- NCT05372614 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in St Louis, MO on ClinicalTrials.gov.
Ask about studies near St Louis
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections